(Total Views: 428)
Posted On: 02/03/2023 8:30:44 AM
Post# of 151

$MRK News Article - Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma https://marketwirenews.com/news-releases/merc...12794.html


My Twitter: WhyteStocks